Loading...
XNASPROF
Market cap209mUSD
Dec 24, Last price  
6.98USD
1D
-0.29%
1Q
-6.56%
IPO
-20.23%
Name

Profound Medical Corp

Chart & Performance

D1W1MN
XNAS:PROF chart
P/E
—
P/S
29.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.11%
Rev. gr., 5y
30.38%
Revenues
7m
+7.75%
0003,900,2381,910,5874,231,5687,304,0006,873,0006,681,0007,199,000
Net income
-29m
L-0.35%
-8,204,40900000-21,622,000-30,699,000-28,669,000-28,569,000
CFO
-22m
L-13.58%
-2,879,14900000-20,574,000-22,360,000-25,800,000-22,297,000
Earnings
Mar 05, 2025

Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
URL
https://profoundmedical.com/
IPO date
Sep 24, 2014
Employees
131
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,199
7.75%
6,681
-2.79%
6,873
-5.90%
Cost of revenue
35,815
36,283
37,164
Unusual Expense (Income)
NOPBT
(28,616)
(29,602)
(30,291)
NOPBT Margin
Operating Taxes
(128)
287
105
Tax Rate
NOPAT
(28,488)
(29,889)
(30,396)
Net income
(28,569)
-0.35%
(28,669)
-6.61%
(30,699)
41.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,601
253
6,376
BB yield
-2.00%
-0.11%
-2.77%
Debt
Debt current
2,363
762
250
Long-term debt
6,415
8,524
2,504
Deferred revenue
728
764
875
Other long-term liabilities
(9,005)
1,106
Net debt
(17,435)
(37,231)
(68,015)
Cash flow
Cash from operating activities
(22,297)
(25,800)
(22,360)
CAPEX
(593)
Cash from investing activities
(593)
Cash from financing activities
1,464
7,031
5,948
FCF
(27,892)
(35,718)
(26,753)
Balance
Cash
26,213
46,517
67,152
Long term investments
3,617
Excess cash
25,853
46,183
70,425
Stockholders' equity
11,493
33,300
63,632
Invested Capital
28,356
18,395
20,344
ROIC
ROCE
EV
Common stock shares outstanding
21,183
20,830
20,464
Price
8.49
-22.04%
10.89
-3.03%
11.23
-45.38%
Market cap
179,840
-20.72%
226,837
-1.29%
229,813
-35.37%
EV
162,405
189,606
161,798
EBITDA
(27,470)
(27,998)
(28,412)
EV/EBITDA
Interest
933
174
303
Interest/NOPBT